Flow Cytometry in Primary Breast Carcinomas: Prognostic Impact of Multiploidy and Hypoploidy

Cytometry Part B - Clinical Cytometry

Volumn 55, Issue 1, 2003, Pages 37-45

  Michels, Jean Jacques ^a   Duigou, Françoise ^a   Marnay, Jacques ^a   Denoux, Yves ^a   Delozier, Thierry ^a   Chasle, Jacques ^a  

^a CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Breast carcinoma; Flow cytometry; Hypoploidy; Micropeaks; Mitotic activity; Multiploidy; Ploidy; S phase fraction

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ANEUPLOIDY; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOREDUPLICATION; FEMALE; FLOW CYTOMETRY; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HYPODIPLOID; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; POPULATION DYNAMICS; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RECEPTOR DENSITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; AGE; BREAST TUMOR; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MIDDLE AGED; MITOSIS INDEX; MORTALITY; PATHOLOGY; RISK FACTOR; STANDARD;

STEROID RECEPTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; PLOIDIES; PROGNOSIS; RECEPTORS, STEROID; RISK FACTORS;

EID: 1542376526     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.10040     Document Type: Article

References (45)

1. Rosai J. Ackerman's surgical pathology. 8th ed. St Louis: Mosby; 1996. p 616-666.
2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978.
3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-2877.
4. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1998;16:793-795.
5. Duigou F, Herlin P, Marnay J, Michels JJ. Variation of flow cytometric DNA measurement in 1,485 primary breast carcinomas according to guidelines for DNA histogram interpretation. Cytometry 2000;42:35-42.
6. Michels JJ, Duigou F, Marnay J. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat 2000;62:117-126.
7. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry 1993;14:482-485.
8. Bagwell CB, Clark GM, Spyratos F, Chassevent A, Bendahl PO, Stal O, et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry 2001;46:121-135.
9. Bracko M, Us-Krasovec M, Cufer T, Lamovec J, Zidar A, Goehde W. Prognostic significance of DNA ploidy determined by high-resolution flow cytometry in breast carcinoma. Anal Quant Cytol Histol 2001;23:56-66.
10. Chassevent A, Jourdan ML, Romain S, Descotes F, Colonna M, Martin PM, et al. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res 2001;7:909-917.
11. Pinto AE, Andre S, Soares J. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol 1999;52:604-611.
12. Balslev I, Christensen IJ, Rasmussen BB, Larsen JK, Lykkesfeldt AE, Thorpe SM, et al. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. Int J Cancer 1994;56:16-25.
13. Chassevent A, Geslin J, Bertrand G, Cellier P, Daver A, Gamelin E, et al. Place de l'analyse de DNA par cytométrie en flux dans l'évaluation du pronostic des cancers du sein. Bull Cancer 1990;77(suppl 1): 149S-154S.
14. Christov K, Milev A, Todorov V. DNA aneuploidy and cell proliferation in breast tumors. Cancer 1989;64:673-679.
15. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988;61:420-427.
16. Frierson HF Jr. Grade and flow cytometric analysis of ploidy for infiltrating ductal carcinomas. Hum Pathol 1993;24:24-29.
17. Lawry J, Rogers K, Duncan JL, Potter CW. The identification of informative parameters in the flow cytometric analysis of breast carcinoma. Eur J Cancer 1993;29A:719-723.
18. Stal O, Wingren S, Carstensen J, Rutqvist LE, Skoog L, Klintenberg C, et al. Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol 1989;25:301-309.
19. Stal O, Carstensen J, Hatschek T, Nordenskjold B. Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients. Br J Cancer 1992;66:706-711.
20. Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjold B. Interrelations between cellular DNA content, S-phase fraction, hormone receptor status and age in primary breast cancer. A series of 1,342 consecutively detected tumors. South-East Sweden Breast Cancer Group. Acta Oncol 1992;31:283-292.
21. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993;28:9-20.
22. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 1993;14:472-477.
23. Bloom HCG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-376.
24. Le DV, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-1921.
25. STATA Reference Manual. 5th ed. 4th release. College Station, TX: Stata Corporation; 1995.
26. Wingren S, Stal O, Sullivan S, Brisfors A, Nordenskjold B. S-phase fraction after gating on epithelial cells predicts recurrence in node-negative breast cancer. Int J Cancer 1994;59:7-10.
27. D'hautcourt JL, Spyratos F, Chassevent A. Quality control study by the French Cytometry Association on flow cytometric DNA content and S-phase fraction (S%). Association Française de Cytometrie. Cytometry 1996;26:32-39.
28. Wenger CR, Clark GM. S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res Treat 1998;51:255-265.
29. Baldetorp B, Ferno M, Fallenius A, Fallenius-Vecchi G, Idvall I, Olsson H, et al. Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 1992;13:577-585.
30. Bergers E, van Diest PJ, Baak JP. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical, and pathologic variables. MMMCP Collaborative Group. Multicenter Morphometric Mammary Carcinoma Project Collaborative Group. Cancer 1996;77:2258-2266.
31. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-633.
32. Ewers SB, Attewell R, Baldetorp B, Borg A, Langstrom E, Killander D. Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat 1992;20:93-108.
33. Ferno M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D. Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol 1992;31:157-165.
34. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990;322:1045-1053.
35. Silvestrini R, Daidone MG, Del Bino G, Mastore M, Luisi A, Di Fronzo G, et al. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 1993;4:213-219.
36. Spyratos F, Briffod M, Gentile A, Brunet M, Brault C, Desplaces A. Flow cytometric study of DNA distribution in cytopunctures of benign and malignant breast lesions. Anal Quant Cytol Histol 1987;9:485-494.
37. Meyer JS, Province MA. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 1994;74:2287-2299.
38. Stal O, Dufmats M, Hatschek T, Carstensen J, Klintenberg C, Rutqvist LE, et al. S-phase fraction is a prognostic factor in stage 1 breast carcinoma. J Clin Oncol 1993;11:1717-1722.
39. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol 2001;54:543-549.
40. Klintenberg C, Stal O, Nordenskjold B, Wallgren A, Arvidsson S, Skoog L. Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat 1986;7(suppl):S99-S106.
41. Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993;71(6 suppl):2157-2162.
42. Muss HB, Kute TE, Case LD, Smith LR, Booher C, Long R, et al. The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 1989;64:1894-1900.
43. Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fossa SD, Tveit KM. Flow cytometric DNA analysis as prognostic factor in human breast carcinoma. Pathol Res Pract 1993;189:405-410.
44. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, et al. Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer 1990;62:786-790.
45. Prasad AR, Divine G, Zarbo RJ. Two-color, cytokeratin-labeled DNA flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up. Arch Pathol Lab Med 2001;125:364-374.